News Focus
News Focus
icon url

biosectinvestor

06/28/25 12:37 PM

#773297 RE: Galzus Research #773292

And you have consistently implied that "real world data" is better to use than clinical trial data collected in a carefully controlled context. You misdirect people with the careful use of terms that effectively you take out of context and make scientifically nonsensical.

No one is excluding pristine trial data to be used, what they are doing when they allow for real world data to be used is EXPANDING THE POTENTIAL DATA SET and making the barriers easier and less burdensome for qualification. It doesn't mean that they are going to disqualify better quality and more statistically relevant data.

I've made this point to you before, in the same context, and you typically do not reply.
icon url

manibiotech

06/28/25 1:49 PM

#773311 RE: Galzus Research #773292

Utter BS as usual.
I posted the MHRA links confirming ECA as a RWD/RWE
Now try better BS that at least will be worth someone's time to read .
icon url

dennisdave

06/28/25 1:59 PM

#773313 RE: Galzus Research #773292

Utter BS once again What the MHRA really said (verbatim):

“Many of the general principles would be relevant for external controls drawn from other sources, such as previously completed clinical trials.”



The MHRA explicitly includes ECAs made from prior clinical trials as being within the scope of the draft.
It says the same methodological standards (pre-specification, bias mitigation, etc.) should apply — not because it’s "real-world data," but because it’s still external and subject to bias. It does not claim clinical trial ECAs are literally equivalent to RWD — but that’s not the point. The point is that both are valid inputs, and the draft is meant to handle both under the same regulatory principles.

The MHRA only applies this guidance to RWD."=> False — it explicitly says the guidance is also relevant for ECAs built from previously completed clinical trials.
"RCT-based ECAs aren't covered under this."=> False — the whole point of the consultation is to give the MHRA policy flexibility for different types of external control arms, including pooled RCTs like those used in DCVax-L.

You are trying to draw a false dichotomy: "If it’s not from electronic health records or insurance data, it can’t be included."
But the MHRA itself is saying: "No — if you're using external controls, whether from real-world settings or old trials, here’s how we’ll evaluate them."
That includes DCVax-L. Period.

Btw you claim the MHRA said something that you made up thats why you refuse to add a link to the MHRA page and quote the MHRA. Ex does that also all the time. Its called lying.